ESMO 2023 | TAR-210 erdafitinib intravesical delivery system in non-muscle invasive bladder cancer
Antoni Vilaseca, MD, Memorial Sloan Kettering Cancer Center, New York, discusses a novel drug delivery system for erdafitinib in treating non-muscle invasive bladder cancer (NMIBC). Erdafitinib, a pan FGFR inhibitor, is effective in advanced urothelial cancer with FGFR mutations. This Phase I study (NCT05316155) introduces TAR-210, a bladder-inserted drug delivery system designed to provide local, continuous release of erdafitinib whilst minimize systemic toxicity. The trial assesses tolerability and efficacy, revealing promising outcomes. In the first cohort, high-risk NMIBC patients with FGFR alterations achieved an 82% disease-free rate. Cohort three, comprising intermediate-risk NMIBC patients with visible tumor lesions, showed an 87% complete response rate. Notably, all responders in the first assessment maintained their response at the study’s cutoff. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP), protected by copyright laws laws and treaties around the world, with all rights reserved.
